Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298291 · ClinicalTrials.gov registry record · NA
Ocular Proteomics Testing In Chronic Atrophy
A NA study of Age-Related (Dry) Macular Degeneration, sponsored by ClinOmicsAI.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07298291 is a NA study of Age-Related (Dry) Macular Degeneration that is actively recruiting participants, run by ClinOmicsAI. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07298291, a NA study of Age-Related (Dry) Macular Degeneration, is actively recruiting participants, sponsored by ClinOmicsAI.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to evaluate the safety of routine diagnostic anterior chamber paracentesis (ACP) for proteomic profiling in patients with geographic atrophy (GA)
Conditions Studied
Interventions
- PROCEDURE AC Tap (anterior chamber paracenthesis)
Study Locations (1)
Pennsylvania
- Erie Retina Research - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-11-30 |
| Est. Completion | 2026-07-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07298291
The ClinicalTrials.gov registry entry for NCT07298291 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ClinOmicsAI, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-Related (Dry) Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which AC Tap (anterior chamber paracenthesis) is the first listed.
NCT07298291 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07298291 about?
NCT07298291 is a clinical study titled "Ocular Proteomics Testing In Chronic Atrophy". Study to evaluate the safety of routine diagnostic anterior chamber paracentesis (ACP) for proteomic profiling in patients with geographic atrophy (GA)
What is the current status of trial NCT07298291?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-11-30. Estimated completion is 2026-07-30.
What conditions does trial NCT07298291 study?
This clinical trial studies the following conditions: Age-Related (Dry) Macular Degeneration.
What interventions are being tested in trial NCT07298291?
The interventions under investigation include: AC Tap (anterior chamber paracenthesis) (PROCEDURE).
Who is sponsoring clinical trial NCT07298291?
This trial is sponsored by ClinOmicsAI, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07298291 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-Related (Dry) Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.